Accordingly, IRX1 is physiologically expressed in MEPs and pro-B-cells, while aberrant expression of IRX2, IRX3 and IRX5 deregulates differentiation processes in AML and BCP-ALL [20, 21, 23]. This evidence concerns the gene IRX3 and acute myeloid leukemia.